Please use this identifier to cite or link to this item:
|Title: ||Antiandrogenic Therapy Can Cause Coronary Arterial Disease|
|Authors: ||CHEN, KUAN-CHOU;PENG, CHIUNG-CHI;HSIEH, HSIU-MEI;PENG, CHIUNG-HUEI;Hsieh, Chiu-Lan;HUANG, CHIEN-NING;CHYAU, CHARNG-CHERNG;WANG, HUI-ER;PENG, ROBERT Y.|
|Keywords: ||Antiandrogen;CAD (coronary arterial disease);CPA (cyproterone acetate);Hormonal therapy;Prostate cancer|
|Issue Date: ||2012-08-07T06:56:49Z
|Publisher: ||John Wiley & Sons, Inc.|
: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate
Materials and methods
: We studied with a 2.5 years follow-up the changes in plasma cholesterols
(C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles
in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN
, Gleason score:
2–5) during treatment with cyproterone acetate (CPA) without surgical management or radiation
: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels
in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of
twenty-four were found to be affected by coronary heart disease.
: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by
prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II
profiles, other than the well-known hyperglyceridemic effect caused by estrogen.
|Relation: ||International Journal of Urology 12(10): 886-891|
|Appears in Collections:||[生物技術研究所] 期刊論文|
Files in This Item:
All items in NCUEIR are protected by copyright, with all rights reserved.